|
|
|
|
|
|
|
Highlights from the 2025 American Urological Association Annual Meeting |
|
|
|
|
| Sasanlimab in Combination with Bacillus Calmette-Guerin Improves Event-Free Survival Versus Bacillus Calmette-Guerin as Standard of Care in High-Risk Non-Muscle-Invasive Bladder Cancer
|
| Neal Shore, MD, FACS
|
| Neal Shore presented results showing that combining sasanlimab, a PD-1 inhibitor, with BCG therapy significantly improved event-free survival compared to BCG alone in high-risk non-muscle-invasive bladder cancer patients. The combination treatment reduced the recurrence of high-grade disease by over 50% and maintained high complete response rates in patients with carcinoma in situ, with a manageable safety profile.
|
|
|
|
|
|
| BOND-003 Cohort C- Phase 3, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma In Situ
|
| Mark Tyson II, MD, MPH |
| The BOND-003 Cohort C study evaluated the efficacy of intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. The treatment achieved a 75.5% complete response rate, with 46.4% maintaining the response at one year and 33.7% at two years, while also demonstrating a high rate of bladder preservation. Cretostimogene grenadenorepvec was well-tolerated, with minimal adverse events and no treatment-related deaths, and it induced a durable immune response, showing potential as a new treatment option for this patient group. |
|
|
|
|
|
| TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin–unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer Carcinoma in Situ: 1-Year Durability and Patient-Reported Outcomes from SunRise-1 Trial
|
| Joseph Jacob, MD, MCR
|
| Joseph Jacob presented data from the SunRise-1 trial, showing that TAR-200, a novel intravesical drug-releasing system, achieved an 82.4% complete response rate in patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). Responses were rapid, with 95.7% of complete responses occurring within 3 months, and durable, with a median duration of response of 25.8 months. The treatment was well tolerated, maintaining quality of life and demonstrating a high cystectomy-free survival rate, with minimal serious adverse events.
|
|
|
|
|
|
|
|
|
|
|
| TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin–unresponsive Papillary Disease–only High-Risk Non–Muscle-Invasive Bladder Cancer: First Results from Cohort 4 of SunRISe-1
|
| Felix Guerrero-Ramos, MD, PhD, FEBU
|
| Felix Guerrero Ramos presented the first results from Cohort 4 of the SunRISe-1 trial, evaluating TAR-200 monotherapy in patients with bacillus Calmette-Guerin (BCG)-unresponsive papillary disease-only high-risk non-muscle-invasive bladder cancer (NMIBC). After 12.8 months of follow-up, the disease-free survival rates at 6 and 9 months were 85.3% and 81.1%, respectively, with only 5.8% of patients requiring radical cystectomy. The treatment was well tolerated, with most adverse events being mild, and high progression-free and overall survival rates were observed at 9 months.
|
|
|
|
|
|
| Crossfire: Controversies in Urology: Double Intravesical Chemotherapy is Preferred Over New FDA Approved Agents for BCG Unresponsive NMIBC: The Price of Success |
| Tullika Garg, MD, MPH, FACS, William Huang, MD, Shreyas Joshi, MD, MPH, Cheryl Lee, MD, and Vignesh Packiam, MD |
| At the AUA 2025 debate on treatment for BCG-unresponsive NMIBC, experts discussed whether double intravesical chemotherapy (gemcitabine/docetaxel) or newly FDA-approved agents like pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept are more effective. Proponents of chemotherapy argued its high efficacy, cost-effectiveness, and favorable safety profile, while supporters of new agents emphasized their potential to activate immune responses and offer less treatment burden, with encouraging long-term data on bladder preservation and survival rates. |
|
|
|
|
|
| Crossfire: Controversies in Urology: Intermediate-Risk Prostate Cancer: Is Focal Therapy a Suitable Option for all Cases?
|
| Samir Taneja, MD, Edward Schaeffer, MD, PhD, Lara Rodríguez Sánchez, MD, PhD, Hashim Ahmed, MD, and Himanshu Nagar, MD, MS
|
| Lara Rodriguez Sanchez, Samir Taneja, Hashim Ahmed, Himanshu Nagar, Edward Schaeffer in a Crossfire: Controversies in Urology debate: discussed if Focal Therapy is a Suitable Option for all Cases with Intermediate-Risk Prostate Cancer.
|
|
|
|
|
|
| State-of-the-Art Lecture: Focal Therapy in Prostate Cancer: Prime Time or Not Time? |
| Samir Taneja, MD |
| Samir Taneja's State-of-the-Art Lecture at AUA 2025 explored the role of focal therapy in prostate cancer treatment. While acknowledging the promising short-term results, including improved quality of life and high locoregional control, he emphasized that focal therapy is most suitable for intermediate-risk patients and should be considered a disease management strategy, not a cure. Despite its potential, focal therapy still faces skepticism due to challenges like MRI limitations, multifocal disease, and a lack of long-term comparative data. |
|
|
|
|
|
| Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle Invasive Bladder Cancer: Results from the C |
| John L. Gore, MD, MS, FACS |
| The CISTO study, presented by Dr. John Gore at AUA 2025, compared radical cystectomy with bladder-sparing therapy for recurrent high-grade non-muscle invasive bladder cancer. At 12 months, although both treatments showed comparable bladder cancer-specific survival, RC was associated with better physical, emotional, and financial well-being outcomes. However, BST showed advantages in bowel and sexual health, with both treatments having distinct benefits depending on patient needs and outcomes.4o mini |
|
|
|
|
|
|
|
|
|
|
